About Connexios Life Sciences
Connexios Life Sciences is a company based in Bengaluru (India) founded in 2003 by Suri Venkatachalam. It operates as a B2B. Connexios Life Sciences has raised $34.25 million across 4 funding rounds from investors including Nadathur. The company has 1 employees as of March 31, 2016. Connexios Life Sciences operates in a competitive market with competitors including Rhythm Pharmaceuticals, MannKind Corp, NGM Biopharmaceuticals, Corcept and ViaCyte, among others.
- Headquarter Bengaluru, India
- Employees 1 as on 31 Mar, 2016
- Founders Suri Venkatachalam
- Stage Minicorn
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
- Legal Name Connexios Life Sciences Private Limited
- Date of Incorporation 25 Jul, 2003
- Jurisdiction Bangalore, Karnataka, India
-
Annual Revenue
$1.05 M (USD)0as on Mar 31, 2016
-
Net Profit
-$3.63 M (USD)0as on Mar 31, 2016
-
EBITDA
-$2.94 M (USD)0as on Mar 31, 2016
-
Total Equity Funding
$34.25 M (USD)
in 4 rounds
-
Latest Funding Round
$18.32 M (USD), Series B
Sep 30, 2016
- Investors
-
Employee Count
1
as on Mar 31, 2016
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Connexios Life Sciences
Connexios Life Sciences has successfully raised a total of $34.25M across 4 strategic funding rounds. The most recent funding activity was a Series B round of $18.32 million completed in September 2016. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Connexios Life Sciences
Connexios Life Sciences has secured backing from 1 investor, including venture fund investors. Prominent investors backing the company include Nadathur.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Investments and philanthropy services offered by Nadathur Group.
|
Locked | Locked | Locked |
Investor details for Connexios Life Sciences
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Connexios Life Sciences
Investment portfolio details for Connexios Life Sciences
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Connexios Life Sciences
Detailed financials for Connexios Life Sciences
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Connexios Life Sciences Comparisons
Peer comparison for Connexios Life Sciences
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Connexios Life Sciences
Connexios Life Sciences operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Rhythm Pharmaceuticals, MannKind Corp, NGM Biopharmaceuticals, Corcept and ViaCyte, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Developer of peptide therapeutics for the treatment of rare genetic deficiencies
|
|
| Locked | Locked | Locked |
Developer of small-molecule drugs
|
|
| Locked | Locked | Locked |
Biologics are developed for cardio-metabolic and liver diseases.
|
|
| Locked | Locked | Locked |
Developer of cortisol modulators for the treatment of various diseases
|
|
| Locked | Locked | Locked |
Cell therapy for diabetes is developed from stem cells.
|
|
| Locked | Locked | Locked |
Developer of therapies for treating nonalcoholic steatohepatitis and other liver and metabolic disorders
|
Detailed competitors of Connexios Life Sciences
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Connexios Life Sciences
Complete news archive for Connexios Life Sciences
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Connexios Life Sciences
Connexios Life Sciences was founded in 2003.
Connexios Life Sciences is headquartered in Bengaluru, India. It is registered at Bengaluru, Karnataka, India.
Suri Venkatachalam is the current CEO of Connexios Life Sciences. They have also founded this company.
Connexios Life Sciences is a funded company, having raised a total of $34.25M across 4 funding rounds to date.
As of Mar 31, 2016, the latest employee count at Connexios Life Sciences is 1.
Annual revenue of Connexios Life Sciences is $1.05M as on Mar 31, 2016.
Connexios Life Sciences develops targeted small molecule drugs for metabolic diseases through providing healthcare solutions, producing pharmaceutical products, drug development, and metabolic diseases. Prioritizing client-centric approaches, it ensures high-quality outcomes, innovation, and sustainable practices in its field. It continues to evolve, meeting industry challenges with strategic approaches.
Connexios Life Sciences's top competitors include Rhythm Pharmaceuticals, MannKind Corp and Corcept.
Connexios Life Sciences has 1 investor. Key investors include Nadathur.
The valuation of Connexios Life Sciences is $34.99M as of Sep 2016.